Evaluation of glucose metrics in adults with type 1 diabetes switching to Insulin Glargine 300 U/mL: a retrospective, propensity-score matched study

Sara Charleer,Steffen Fieuws,Christophe De Block,Nancy Bolsens,Frank Nobels,Kristian Mikkelsen,Chantal Mathieu,Pieter Gillard
DOI: https://doi.org/10.1089/dia.2023.0371
2024-02-23
Diabetes Technology & Therapeutics
Abstract:OBJECTIVES To study real-world effect of switching to Insulin Glargine 300 U/mL (Gla-300) on glucose metrics in people with type 1 diabetes (T1D). METHODS This retrospective secondary-use study compared 151 adults who switched to Gla-300 from first-generation long-acting insulins (Switchers) to 281 propensity-score matched controls (Non-switchers) who continued first-generation long-acting insulins. Primary endpoint was difference in time in range (TIR) evolution. A fictive "switching" date was assigned to Non-switchers to facilitate between-group comparisons. RESULTS In the period before switching, TIR decreased numerically for people in whom Gla-300 was eventually initiated (-0.05%/month [-0.16;0.07]), while it increased for matched controls (0.08%/month [0.02;0.015]; between-group difference p=0.047). After Gla-300-initiation, Switchers had similar TIR increase compared to Non-switchers (p=0.531). Switchers used higher basal dose than before switch (Δ0.012 U/kg/day [0.006;0.018]; p<0.0001). CONCLUSION In real-life, Gla-300 was typically initiated in people where TIR was decreasing, which was reversed after switch using slightly higher basal insulin dose.
endocrinology & metabolism
What problem does this paper attempt to address?